Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice.
作者信息
Al-Ibraheem Akram
机构信息
Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan.
Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan.
出版信息
World J Nucl Med. 2023 Sep 20;22(3):171-173. doi: 10.1055/s-0043-1774733. eCollection 2023 Sep.
Abstract
摘要
相似文献
1
Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice.
World J Nucl Med. 2023 Sep 20;22(3):171-173. doi: 10.1055/s-0043-1774733. eCollection 2023 Sep.
2
The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective.
J Nucl Med. 2022 Jun;63(6):819-822. doi: 10.2967/jnumed.122.263996. Epub 2022 Apr 7.
3
Medical practice in the face of economic meltdown: peculiar challenges in Nigeria and other developing countries.
Niger J Med. 2009 Oct-Dec;18(4):360-4. doi: 10.4314/njm.v18i4.51225.
4
Organic agriculture and undernourishment in developing countries: main potentials and challenges.
Crit Rev Food Sci Nutr. 2013;53(9):917-28. doi: 10.1080/10408398.2011.573886.
5
Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine.
OMICS. 2023 Jan;27(1):6-14. doi: 10.1089/omi.2022.0151. Epub 2023 Jan 4.
6
Radiation protection infrastructure-challenges in developing countries.
J Radiol Prot. 2021 Aug 19;41(3). doi: 10.1088/1361-6498/ac0c00.
7
Advanced Physiotherapy Practice: A qualitative study on the potential challenges and barriers to implementation in Ghana.
Physiother Theory Pract. 2020 Feb;36(2):307-315. doi: 10.1080/09593985.2018.1484535. Epub 2018 Jun 13.
8
Screening for hyperglycemia in the developing world: rationale, challenges and opportunities.
Diabetes Res Clin Pract. 2012 Nov;98(2):199-208. doi: 10.1016/j.diabres.2012.08.003. Epub 2012 Sep 10.
9
U.S. trainees' experiences of ethical challenges during research in low- and middle-income countries: A mixed methods study.
Glob Public Health. 2022 Jul;17(7):1433-1449. doi: 10.1080/17441692.2021.1933124. Epub 2021 Jun 1.
10
Pharmacogenomics, Theranostics and Personalized Medicine - the complexities of clinical trials: challenges in the developing world.
Appl Transl Genom. 2013 May 14;2:17-21. doi: 10.1016/j.atg.2013.05.002. eCollection 2013 Dec 1.
引用本文的文献
1
Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during Lu/Ac treatment in neuroendocrine tumors and metastatic prostate cancer.
Theranostics. 2025 Mar 18;15(10):4368-4397. doi: 10.7150/thno.107963. eCollection 2025.
2
Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review.
Nucl Med Mol Imaging. 2025 Feb;59(1):50-61. doi: 10.1007/s13139-024-00891-0. Epub 2024 Nov 12.
3
Analysis of Molecular Imaging Biomarkers Derived from [F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [Ac]Ac-PSMA-617-Augmented [Lu]Lu-PSMA-617 Radioligand Therapy.
Cancers (Basel). 2024 Oct 19;16(20):3532. doi: 10.3390/cancers16203532.
4
A New Era for PET/CT: Applications in Non-Tumorous Renal Pathologies.
J Clin Med. 2024 Aug 7;13(16):4632. doi: 10.3390/jcm13164632.
5
Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival.
Cancers (Basel). 2024 Jul 26;16(15):2670. doi: 10.3390/cancers16152670.
6
Efficacy and safety of rechallenge [Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).
Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4151-4162. doi: 10.1007/s00259-024-06825-4. Epub 2024 Jul 15.
7
From Despair to Hope: First Arabic Experience of Lu-PSMA and Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer.
Cancers (Basel). 2024 May 23;16(11):1974. doi: 10.3390/cancers16111974.
8
Intense prostate-specific membrane antigen receptor expression in coronary artery pypass graft scar tissue: A potential molecular imaging pitfall.
Acta Radiol Open. 2024 Mar 28;13(2):20584601241240318. doi: 10.1177/20584601241240318. eCollection 2024 Feb.
9
[Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lu]Lu-PSMA-617.
Theranostics. 2024 Feb 24;14(5):1829-1840. doi: 10.7150/thno.92273. eCollection 2024.
10
Guiding principles on the education and practice of theranostics.
Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2320-2331. doi: 10.1007/s00259-024-06657-2. Epub 2024 Mar 8.
本文引用的文献
1
Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer.
Nucl Med Mol Imaging. 2023 Aug;57(4):168-171. doi: 10.1007/s13139-023-00804-7. Epub 2023 Apr 26.
2
Tb-PSMA Radioligand Therapy: First-in-Humans SPECT/CT Imaging.
J Nucl Med. 2023 Aug;64(8):1322-1323. doi: 10.2967/jnumed.122.265291. Epub 2023 Feb 9.
3
Cancer diagnosis in areas of conflict.
Front Oncol. 2022 Dec 22;12:1087476. doi: 10.3389/fonc.2022.1087476. eCollection 2022.
4
The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective.
J Nucl Med. 2022 Jun;63(6):819-822. doi: 10.2967/jnumed.122.263996. Epub 2022 Apr 7.
5
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.
6
Diagnostic Performance and Clinical Impact of Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study).
J Nucl Med. 2022 Feb;63(2):240-247. doi: 10.2967/jnumed.120.261886. Epub 2021 Jul 2.
7
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
8
Status of Nuclear Medicine in Latin America and the Caribbean: IAEA Analysis of Development in the Past 6 Years.
J Nucl Med. 2021 Jun 1;62(6):23N-29N.
9
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.
J Nucl Med. 2020 Dec;61(Suppl 2):263S-272S. doi: 10.2967/jnumed.120.254532.
10
Theranostic approaches in nuclear medicine: current status and future prospects.
Expert Rev Med Devices. 2020 Apr;17(4):331-343. doi: 10.1080/17434440.2020.1741348. Epub 2020 Mar 19.
Zotero 插件